Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

R E Ratner, J Rosenstock, G Boka, DRI6012 Study Investigators, Timothy Lyons

Research output: Contribution to journalArticlepeer-review

124 Citations (Scopus)

Abstract

To evaluate the dose-response relationship of lixisenatide (AVE0010), a glucagon-like peptide-1 (GLP-1) receptor agonist, in metformin-treated patients with Type 2 diabetes.
Original languageEnglish
Pages (from-to)1024-32
Number of pages9
JournalDiabetic Medicine
Volume27
Issue number9
DOIs
Publication statusPublished - Sep 2010

Keywords

  • Adult
  • Aged
  • Blood Glucose
  • Diabetes Mellitus, Type 2
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Resistance
  • Female
  • Hemoglobin A, Glycosylated
  • Humans
  • Hypoglycemic Agents
  • Male
  • Metformin
  • Middle Aged
  • Peptides
  • Placebos
  • Receptors, Glucagon

Fingerprint

Dive into the research topics of 'Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial'. Together they form a unique fingerprint.

Cite this